Profile data is unavailable for this security.
About the company
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
- Revenue in USD (TTM)0.00
- Net income in USD-69.42m
- Incorporated2017
- Employees58.00
- LocationLexeo Therapeutics Inc345 Park Avenue South, Floor 6NEW YORK 10010United StatesUSA
- Phone+1 (212) 547-9879
- Fax+1 (302) 636-5454
- Websitehttps://www.lexeotx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PepGen Inc | 0.00 | -80.33m | 442.13m | 64.00 | -- | 2.47 | -- | -- | -3.25 | -3.25 | 0.00 | 5.53 | 0.00 | -- | -- | 0.00 | -39.37 | -- | -42.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Cibus Inc | 2.32m | -285.67m | 453.51m | 183.00 | -- | 1.39 | -- | 195.48 | -18.29 | -18.29 | 0.1522 | 13.24 | 0.0084 | -- | -- | 12,677.60 | -129.84 | -86.28 | -147.90 | -96.45 | -- | -- | -15,483.49 | -792.07 | -- | -3.17 | 0.0039 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| ACELYRIN Inc | 0.00 | -240.16m | 457.97m | 130.00 | -- | 0.7107 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Biomea Fusion Inc | 0.00 | -127.27m | 459.37m | 110.00 | -- | 3.39 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -69.42m | 461.89m | 58.00 | -- | 2.52 | -- | -- | -2.71 | -2.71 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -47.71 | -- | -54.30 | -- | -- | -- | -- | -- | -- | -- | 0.0091 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Theravance Biopharma Inc | 61.51m | -44.77m | 466.18m | 99.00 | -- | 2.28 | -- | 7.58 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Cartesian Therapeutics Inc | 25.91m | -254.87m | 468.75m | 38.00 | -- | -- | -- | 18.09 | -48.02 | -48.02 | 4.94 | -21.18 | 0.1077 | -- | 5.86 | 681,736.80 | -106.00 | -43.66 | -122.03 | -66.84 | -- | -- | -983.83 | -136.35 | -- | -0.5249 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Voyager Therapeutics Inc | 119.04m | -3.04m | 469.37m | 162.00 | -- | 1.38 | 309.20 | 3.94 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Tscan Therapeutics Inc | 14.81m | -96.80m | 470.48m | 161.00 | -- | 3.47 | -- | 31.76 | -1.28 | -1.28 | 0.1784 | 2.57 | 0.0715 | -- | -- | 96,181.82 | -46.72 | -- | -52.48 | -- | -- | -- | -653.50 | -- | -- | -- | 0.1974 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Fate Therapeutics Inc | 6.48m | -190.05m | 471.26m | 181.00 | -- | 1.11 | -- | 72.75 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Larimar Therapeutics Inc | 0.00 | -45.08m | 474.05m | 42.00 | -- | 2.05 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| Korro Bio Inc | 0.00 | -81.19m | 475.33m | 94.00 | -- | 2.72 | -- | -- | -43.16 | -43.16 | 0.00 | 18.87 | 0.00 | -- | -- | 0.00 | -54.22 | -31.55 | -60.95 | -36.48 | -- | -- | -- | -365.87 | -- | -357.64 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Nkarta Inc | 0.00 | -116.20m | 480.59m | 150.00 | -- | 1.01 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Editas Medicine Inc | 69.41m | -166.13m | 484.38m | 265.00 | -- | 1.65 | -- | 6.98 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Data as of May 17 2024. Currency figures normalised to Lexeo Therapeutics Inc's reporting currency: US Dollar USD
47.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Eventide Asset Management LLCas of 31 Dec 2023 | 3.00m | 11.27% |
| D1 Capital Partners LPas of 31 Dec 2023 | 2.51m | 9.41% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 2.33m | 8.74% |
| Citadel Advisors LLCas of 31 Dec 2023 | 2.08m | 7.82% |
| Blackstone Alternative Asset Management LPas of 31 Dec 2023 | 696.11k | 2.61% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 603.44k | 2.27% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 577.88k | 2.17% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 468.51k | 1.76% |
| Laurion Capital Management LPas of 31 Dec 2023 | 255.30k | 0.96% |
| Verition Fund Management LLCas of 31 Dec 2023 | 189.06k | 0.71% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
